Literature DB >> 18579347

Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression.

Katharina Domschke1, Udo Dannlowski, Patricia Ohrmann, Bruce Lawford, Jochen Bauer, Harald Kugel, Walter Heindel, Ross Young, Phillip Morris, Volker Arolt, Jürgen Deckert, Thomas Suslow, Bernhard T Baune.   

Abstract

The endocannabinoid system has been implicated in the pathogenesis of depression and anxiety, the mediation of antidepressant drug effects in animal models and the neurobiology of emotion processing in healthy volunteers. Therefore, the impact of cannabinoid receptor 1 gene (CNR1) variants rs1049353 and rs12720071 on antidepressant treatment response was evaluated in 256 Caucasian patients with Major Depression. A subsample of 33 depressed patients was additionally scanned by fMRI under visual presentation of emotional faces. The CNR1 rs1049353 G allele conferred an increased risk of antidepressant treatment resistance, particularly in female patients with high comorbid anxiety. CNR1 rs1049353 G allele carriers also demonstrated weaker bilateral amygdala, putamen and pallidum activity as well as left lateralized caudate and thalamus activity in response to masked happy faces. This analysis provides preliminary support for a role of CNR1 gene variation in depression and anxiety, potentially mediated by subcortical hypo-responsiveness to social reward stimuli.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579347     DOI: 10.1016/j.euroneuro.2008.05.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  61 in total

1.  Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Behav Brain Res       Date:  2015-12-09       Impact factor: 3.332

Review 2.  [Neurogenetics of emotional processes. Neuroimaging findings as endophenotypes for depression].

Authors:  U Dannlowski; C Konrad; V Arolt; T Suslow
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

Review 3.  Endocannabinoid-mediated synaptic plasticity and addiction-related behavior.

Authors:  Nimish Sidhpura; Loren H Parsons
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 5.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 6.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

Review 7.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

8.  Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders.

Authors:  Susana Mato; Fuencisla Pilar-Cuéllar; Elsa M Valdizán; Javier González-Maeso; Rafael Rodríguez-Puertas; Javier Meana; Joan Sallés; Benedicto Crespo-Facorro; Ángel Pazos
Journal:  Biochem Pharmacol       Date:  2018-08-10       Impact factor: 5.858

9.  Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response.

Authors:  Katharina Domschke; Nicola Tidow; Kathrin Schwarte; Christiane Ziegler; Klaus-Peter Lesch; Jürgen Deckert; Volker Arolt; Peter Zwanzger; Bernhard T Baune
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

Review 10.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.